Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BLU-924
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BLU-924 (also known as SAR449336) is an orally bioavailable, potent, and selective pan-KRAS inhibitor developed by Blueprint Medicines in collaboration with Sanofi. It is designed to target multiple KRAS mutations, including G12D, G12V, and G13D, as well as the wild-type KRAS protein. By inhibiting KRAS, BLU-924 disrupts the MAPK signaling pathway, which is frequently dysregulated in various solid tumors. It is currently being evaluated in Phase 1/2 clinical trials for the treatment of advanced pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer harboring KRAS mutations, both as a monotherapy and in combination with other agents.
02
Targets
Beyond the preview
Go deeper on BLU-924.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BLU-924.